202 related articles for article (PubMed ID: 12358949)
1. STI-571 in chronic myelogenous leukaemia.
Tsao AS; Kantarijian H; Talpaz M
Br J Haematol; 2002 Oct; 119(1):15-24. PubMed ID: 12358949
[No Abstract] [Full Text] [Related]
2. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
Parmar KK; King RS
Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
[No Abstract] [Full Text] [Related]
3. After imatinib: new hopes for chronic myeloid leukaemia.
Bradbury J
Drug Discov Today; 2005 Apr; 10(8):536-7. PubMed ID: 15837592
[No Abstract] [Full Text] [Related]
4. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
[No Abstract] [Full Text] [Related]
5. 3. Imatinib therapy in chronic myelogenous leukemia.
Jinnai I
Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
[No Abstract] [Full Text] [Related]
6. Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance.
Sandoval C; Giamelli J; Jayabose S
J Pediatr Hematol Oncol; 2003 Jun; 25(6):507-8. PubMed ID: 12794534
[No Abstract] [Full Text] [Related]
7. Position paper on imatinib mesylate in chronic myeloid leukaemia.
O'Brien SG; Rule SA
Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935
[No Abstract] [Full Text] [Related]
8. NICE widens patient group for leukaemia drug.
Kmietowicz Z;
BMJ; 2002 Oct; 325(7369):852. PubMed ID: 12386018
[No Abstract] [Full Text] [Related]
9. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
White DL
Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
[No Abstract] [Full Text] [Related]
10. New directions in the treatment of patients with chronic myeloid leukemia: introduction.
Baccarani M
Semin Hematol; 2009 Apr; 46(2 Suppl 3):S1-4. PubMed ID: 19621542
[No Abstract] [Full Text] [Related]
11. Imatinib for chronic myeloid leukaemia: a NICE mess.
Barbour V
Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
[No Abstract] [Full Text] [Related]
12. [Treatment of chronic myelogenous leukemia by using imatinib].
Jinnai I
Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1819-24. PubMed ID: 16223141
[No Abstract] [Full Text] [Related]
13. Activity of AMN107 in gleevec-resistant leukemia.
Cancer Biol Ther; 2006 Jan; 5(1):8. PubMed ID: 16924763
[No Abstract] [Full Text] [Related]
14. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
[No Abstract] [Full Text] [Related]
15. Doctors condemn NICE's guidance on leukaemia drug.
Mayor S
BMJ; 2002 Jun; 324(7350):1352. PubMed ID: 12052793
[No Abstract] [Full Text] [Related]
16. Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
Mesa RA; Steensma DP; Hoyer J; Ketterling RP
Br J Haematol; 2003 Oct; 123(2):366-7. PubMed ID: 14531922
[No Abstract] [Full Text] [Related]
17. Imatinib for chronic myeloid leukaemia: a NICE mess.
Rajaratnam G; Edwards J
Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
[No Abstract] [Full Text] [Related]
18. After 30 years of laboratory work, a quick approval for STI571.
Arnold K
J Natl Cancer Inst; 2001 Jul; 93(13):972. PubMed ID: 11438558
[No Abstract] [Full Text] [Related]
19. Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?
Yeung DT; White DL
Leuk Lymphoma; 2011 Feb; 52(2):165-7. PubMed ID: 21171867
[No Abstract] [Full Text] [Related]
20. Imatinib for chronic myeloid leukaemia: a NICE mess.
Lim D; Muir J
Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
[No Abstract] [Full Text] [Related]
[Next] [New Search]
